Overview
A Study to Evaluate ITCA 650 Compared to Sitagliptin as add-on Therapy for the Treatment of Type 2 Diabetes
Status:
Completed
Completed
Trial end date:
2015-07-01
2015-07-01
Target enrollment:
0
0
Participant gender:
All
All
Summary
Phase 3 study to compare treatment with ITCA 650 to sitagliptin when added to metformin monotherapy in patients with type 2 diabetes.Phase:
Phase 3Accepts Healthy Volunteers?
NoDetails
Lead Sponsor:
Intarcia TherapeuticsTreatments:
Exenatide
Sitagliptin Phosphate
Criteria
Inclusion Criteria:- HbA1c between 7.5% - 10.5%
- on metformin monotherapy
- BMI between 25 & 45 kg/m2
Exclusion Criteria:
- taking thiazolidinedione, sulfonylurea, DPP-4, exenatide, alpha glucosidase
inhibitors, meglitinides or insulin within last 3 months
- history of pancreatitis